Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche
Zealand Pharma shares rose sharply after the Danish pharmaceutical company struck a licensing and collaboration deal of up to $5.3 billion with Roche. Shares in Zealand were up 25% at 609 Danish kroner in European morning trading Wednesday, but remained down 25% since the start of the year. Roche shares traded 4.1% higher at 308.50 Swiss francs.
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
committing $1.65 billion up front to partner on a clinical-stage Zealand Pharma molecule with the potential to be a standalone treatment and part of drug combinations for weight loss. The deal ...
Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback